Compare Danaher Corporation (DHR) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Gogoro Inc — how do they compare? Danaher Corporation trades at $220.38 (market cap $152.87B), while Gogoro Inc trades at $2.89 (market cap $56.21M). The key difference: Danaher Corporation is far larger — about 2719.6× Gogoro Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Gogoro Inc for 14 Days on average.
| DHR | GGR | |
|---|---|---|
Market Cap | $152.87B | $56.21M |
Volume | 5,228,698 | 14,026 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $5.15 |
52-Week Low | $161.91 | $2.20 |
Typical Hold Time | 69 Days | 14 Days |
Enterprise Value | $175.08B | $342.65M |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
GGR trades at $2.99, down 6.27% today, with a bullish technical signal from moving averages but negative profitability metrics including a -16.68% net income margin. Recent developments include new board appointments and a $61.8 million equity investment announced in October 2026. The company shows revenue growth from $281 million in 2025 to $286 million projected for 2026, though net losses persist.
The outlook remains cautious with 100% hold ratings from analysts. Investment appeal lies in the low P/S of 0.18 and EV/EBITDA of 6.38, but risks include sustained negative cash flow and high debt-to-asset ratio of 60%. Positive technical momentum contrasts with fundamental challenges in achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
